^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Xolremdi (mavorixafor)

    i
    Other names: X4P-001, AMD11070, AMD-070, AMD-11070, X4P001, X4P 001, X4P-001-RD, X4P-001-IO, AMD11070 - WHIM, ABSK-081, ABSK081
    Company:
    Abbisko, Norgine, X4 Pharma, taiba
    Drug class:
    CXCR4 antagonist
    Related drugs:
    2d
    Oral CXCR4 inhibition with mavorixafor: Emerging therapeutic applications in WHIM syndrome, chronic neutropenia, oncology, and stem cell mobilization. (PubMed, Curr Res Transl Med)
    Furthermore, this review positions mavorixafor within the broader CXCR4-targeted therapeutic landscape, identifying current research gaps and suggesting directions for future studies. In conclusion, by integrating mechanistic insights with preclinical and clinical findings, this article highlights mavorixafor's promise as a targeted therapy with the potential to transform treatment paradigms for CXCR4-driven diseases.
    Review • Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
    |
    Xolremdi (mavorixafor)
    1m
    C-X-C chemokine receptor type 4 (CXCR4) antagonism in precision oncology: Clinical applications and future directions. (PubMed, Cancer Pathog Ther)
    Antagonistic peptides AMD3100 (Plerixafor), LY2510924, and POL6326, as well as their therapeutic potential. Future research on Mavorixafor will focus on two main areas: personalized medicine development, new delivery systems and their broad medical applications extending beyond oncology. As a potential CXCR4 antagonist, Mavorixafor shows promise as a transformative tool in cancer care because it regulates the tumor microenvironment (TME) while increasing the degree of therapeutic benefits.
    Review • Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
    |
    Xolremdi (mavorixafor) • balixafortide (POL 6326) • LY2510924 • plerixafor
    5ms
    A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections (clinicaltrials.gov)
    P3, N=176, Recruiting, X4 Pharmaceuticals | Trial completion date: Aug 2026 --> Nov 2027 | Trial primary completion date: Jul 2026 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    Xolremdi (mavorixafor)
    8ms
    Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome (clinicaltrials.gov)
    P3, N=31, Active, not recruiting, X4 Pharmaceuticals | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    Xolremdi (mavorixafor)
    9ms
    Drug-Drug Interaction Potential of Mavorixafor (clinicaltrials.gov)
    P1, N=38, Completed, X4 Pharmaceuticals | Recruiting --> Completed
    Trial completion
    |
    Xolremdi (mavorixafor) • efavirenz
    11ms
    Synthesis and 64Cu-Radiolabeling Strategies of Small Organic Radioconjugates Based on the AMD070 Scaffold. (PubMed, ChemMedChem)
    These are based mainly on nitrogen-rich scaffolds, such as AMD070, and cyclic polyamines such as cyclam in the AMD3100 skeleton. Herein, we describe the synthesis of two novel CXCR4-directed radiopharmaceuticals, combining the AMD070 scaffold as a targeting unit, and bifunctional te1pa macrocycle as a strong 64Cu chelator. The synthesis of the conjugates and optimization of 64Cu-radiolabeling are presented, opening the way for future in vitro and in vivo studies.
    Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    Xolremdi (mavorixafor) • plerixafor
    1year
    Drug-Drug Interaction Potential of Mavorixafor (clinicaltrials.gov)
    P1, N=36, Recruiting, X4 Pharmaceuticals
    New P1 trial
    |
    Xolremdi (mavorixafor) • efavirenz
    1year
    A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function (clinicaltrials.gov)
    P1, N=48, Recruiting, X4 Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Xolremdi (mavorixafor)
    1year
    A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, X4 Pharmaceuticals
    New P1 trial
    |
    Xolremdi (mavorixafor)
    over1year
    Grafting a chromophore on AMD070 analogues for CXCR4 bioimaging: Chemical synthesis and in vitro assessment of the inhibition properties of the CXCR4 receptor. (PubMed, Bioorg Med Chem Lett)
    Thank to their particular pharmacokinetics, the use of small organic molecules can be a very promising alternative to macromolecular targeting biomolecules (i.e. antibodies, peptides…) for specific imaging of tumours. Herein, the potential of two AMD070-like inhibitors as CXCR4-targeting units for specific imaging of cancer cells, and the influence of chromophore-grafting on their recognition properties has been investigated.
    Preclinical • Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    Xolremdi (mavorixafor)
    over1year
    A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders (clinicaltrials.gov)
    P1/2, N=32, Completed, X4 Pharmaceuticals | Active, not recruiting --> Completed | Trial completion date: Jul 2025 --> Aug 2024 | Trial primary completion date: Jun 2025 --> Aug 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    Xolremdi (mavorixafor)
    over1year
    A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 (clinicaltrials.gov)
    P1, N=16, Completed, X4 Pharmaceuticals | Phase classification: P1b --> P1
    Phase classification • Combination therapy
    |
    Imbruvica (ibrutinib) • Xolremdi (mavorixafor)